A
Agendia
Molecular diagnostics and personalized treatment plans for cancer patients
About Agendia
Agendia is a healthcare startup specializing in molecular diagnostics and personalized medicine, particularly in the field of cancer diagnostics. The company operates in the healthcare market, serving clients such as hospitals, clinics, and other healthcare providers. Its business model revolves around the development and commercialization of innovative diagnostic tools and therapies, which are designed to improve patient outcomes and reduce healthcare costs.
Read full description
The company's leadership team is composed of seasoned professionals with extensive experience in healthcare, diagnostics, and pharmaceuticals. This includes Kenyon Sweeney, who leads the commercial function, and Christy Garcia, who oversees compliance. The company's financial management and operations are led by Kurt, who has over fifteen years of experience in financial management and analytics in healthcare, banking, and aerospace industries. The company's research efforts are spearheaded by Prof. Laura van ‘t Veer, a recognized pioneer in the field of personalized medicine.
Agendia generates revenue through the sale of its diagnostic products and services to healthcare providers. The company's focus on personalized medicine, which involves tailoring medical treatment to individual patient characteristics, positions it well in a market that is increasingly recognizing the value of such approaches.
At a glance
- Status
- Operational
- Founded
- 2003
- Headquarters
- Irvine, United States
- Employees
- 221
- Open positions
- 7
- Dealroom signal
- 75.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, Patient Care, Molecular, Spinout, Sustainable Development Goals, Seal of Excellence EC, Horizon Europe, medical testing
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Agendia.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Jul 2018 | $35M | — | Athyrium Capital Management | ↗ |
| GRANTOther financing | Jul 2015 | $4.4M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Agendia is 7.3K monthly website visits, down 24.7% over the last three months. Agendia's team grew 2.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Innovation Council
Series A2 investors entered at this stage
- GVGlobal Life Science Ventures
Atlantic Vantage Point
Series B and later8 investors entered at this stage
Gilde Healthcare
Van Herk Investments
ING Bank Corporate Finance
ING Group
Debiopharm Group
ING Corporate Investments
Norgine Ventures
Athyrium Capital Management
Other known investors1 additional known investor
Netherlands Cancer Institute (NKI)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Agendia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Agendia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.